Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Nucleotides in development at Inspire for various clinical indications

July 20, 2000

Alcon claims use of AIT-082 and other neurotrophic factor enhancers in ophthalmic disorders

July 5, 2000

New market launch for Azopt

June 30, 2000

Dura to launch second Allergan product

June 20, 2000

Alcon discovers utility of glutamate antagonists for retinal disorders

June 9, 2000

Allergan and Xoma expand rBPI ophthalmic program

June 6, 2000

Visudyne therapy receives Canadian approval for treatment of wet AMD

June 2, 2000

Angiotech signs license agreement with Alcon for delivery of paclitaxel

May 30, 2000

Early use of PDT with verteporfin in age-related macular degeneration

May 24, 2000

New agents for cataracts designed by Sankyo

May 22, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...